

Eff. Date: 2 June 2023 Version: 2.1 IFU: MSH2 ILM8734

# MSH2 clone G219-1129

# Instructions for Use

### Specification:

MSH2 is a mismatch repair gene which is deficient in a high proportion of patients with microsatellite instability (MSI-H). This finding is associated with the autosomal dominant condition known as Hereditary Non-Polyposis Colon Cancer (HNPCC). The anti-MSH2 antibody is useful in screening patients and families for this condition. Colon cancers that are microsatellite unstable have a better prognosis than their microsatellite stable counterparts.

#### Availability:

Catalog No.	Contents	Volume
ILM8734-C01	MSH2	0,1 ml concentrate
ILM8734-C05	MSH2	0,5 ml concentrate
ILM8734-C1	MSH2	1,0 ml concentrate

Intended use: For Research Use Only

Reactivity: Human

Clone: G219-1129

Species of origin: Mouse

Isotype: IgG1

Control Tissue: Colon cancer, colon mucosa

Staining: Nuclear

Presentation: MSH2 (G219-1129) primary antibody in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

#### Application and suggested dilutions:

Pre-treatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section
- (dilution 1:200-1:400) The optimal dilution for a specific application should be determined by the investigator.

**Note:** Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

## **References:**

- 1) Wright, CL et al, Am J Surg Pathol. 2003; 27:1393-1406.
- 2) Brueckl, WM et al, Anticancer Research 2003; 23:1773-1778.
- 3) Rigau, V et al, Arch Pathol Lab Med 2003 June; 127(6):694-700.
- 4) Renkonen, E et al, J Clin Oncol 2003; 21:3629-3637.
- 5) Hoedema, R et al, The American Surgeon 2003 May; 69(5):387-92.
- 6) Christensen, M et al, Cancer 2002; 95:2422-30.
- 7) Wahlberg, SS et al, Cancer Research June 15 2002; 62:3485-3492.
- 8) Lanza, G et al, Modern Pathology 2002; 15:741-749.

WellMed BV, Delta 52, 6825 MS, Arnhem, The Netherlands + 31 (0) 85 273 23 23 info@wellmed.nl www.wellmed.nl

